Autopsy report · NCT05116800

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

“IND withdrawn”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Brown University

Sponsor type

University, hospital or other

Conditions

Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Leiomyosarcoma; Liposarcoma; Angiosarcoma

Interventions

Gemcitabine; 9-ING-41; Docetaxel

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia
  “Withdrawn for administrative reasons.” (68% match in meaning)
• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (66% match in meaning)
• Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
  “Withdrawn due to poor accrual” (66% match in meaning)
• RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
  “Protocol was withdrawn from IND” (66% match in meaning)
• MAGIK for Femoral/Tibial Shaft Fractures
  “Withdrawn due to lack of funding.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.